Recon: FDA staff find Guardant test may not identify certain pre-cancerous tumors; AstraZeneca targets $80B in revenue and 20 new therapies by 2030
ReconJason Scott
Advisory committeesBiotechnologyEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicySubmission and registrationUnited States